Fenoxaprop-ethyl (organic nitrate combined with L-arginine), is an oral proprietary nitrate therapeutic shown to induce coronary vasodilation while overcoming the significant problem of drug tolerance. Fenoxaprop-ethyl has been investigated to... Fenoxaprop-ethyl has been investigated to treat chronic angina, the chest pain that occurs from inadequate blood flow to the coronary arteries around the heart.
- Mechanism
- Curator reviewed
Fenoxaprop-ethyl is a proprietary combination of nitrate and L-arginine that provides the beneficial cardiovascular effects of nitrates. Combining L-arginine with organic nitrates prevents the endothelial cell's depletion of L-arginine and the associated problem of nitrate tolerance. By eliminating nitrate tolerance, Fenoxaprop-ethyl allows patients to receive the continuous, 24-hour benefit of a potent nitrate product, thus sustaining the desired vasodilation effect.
- Primary indication
- Chronic angina and Coronary Artery DiseaseCurator reviewed
- Formula / weight
- C18H16ClNO5 · 361.776 g/mol (avg)
- Also known as
- Fenoxaprop ethyl
- Code names
- HOE 33171 · HOE-A 25-01
Resolves to
PQKBPHSEKWERTG-UHFFFAOYSA-NSMILESCCOC(=O)C(C)OC1=CC=C(OC2=NC3=C(O2)C=C(Cl)C=C3)C=C1What you can answer from here — as of March 06, 2025
Which drugs share a target with Fenoxaprop-ethyl, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account